- £167.19bn
- £186.67bn
- $54.07bn
- 96
- 19
- 82
- 77
REG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Fixed-duration Calquence approved in EU for 1L CLL
AnnouncementREG - AstraZeneca PLC - Block listing Interim Review
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Imfinzi recommended in EU for bladder cancer
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Director Declaration
AnnouncementREG - AstraZeneca PLC - Acquisition of EsoBiotec completed
AnnouncementREG - AstraZeneca PLC - Imfinzi improved DFS in early bladder cancer
AnnouncementREG - AstraZeneca PLC - Enhertu improved pCR in early-stage breast cancer
AnnouncementRCS - Redx Pharma Limited - Redx presents Ph1 data supporting RXC008 at DDW
AnnouncementREG - AstraZeneca PLC - Calquence combination approved in EU for 1L MCL
AnnouncementREG - AstraZeneca PLC - Breztri met primary endpoints in Ph3 asthma trials
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Fixed-duration Calquence recommended in EU for CLL
AnnouncementREG - AstraZeneca PLC - Update on CAPItello-280 Phase III trial
AnnouncementREG - AstraZeneca PLC - 1st Quarter Results
AnnouncementREG - AstraZeneca PLC - Enhertu combination improved PFS in 1L HER2+ mBC
Announcement